Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

One year later, 40% of patients with COVID pneumonia still had lung problems

A recent study published in the journal Respiratory Research found impaired lung function and dyspnea amongst severe COVID-19 pneumonia survivors one year post-infection. Meanwhile, many COVID-19 patients developed fibrotic-like sequelae as an aftermath of the infection-associated mild or severe pneumonia.

15 Sep 2022

Study reveals pan-antiviral properties of PDC-109 bovine seminal plasma protein

In a new study, researchers explored the antiviral activity of the bovine seminal plasma protein PDC-109 against various mammalian viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

What is the COVID-19 prevalence among neonates?

A new study evaluated the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in newborns.

15 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

Bivalent recombinant vaccine protects against SARS-CoV-2 and influenza in animal models

In a new study, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.

15 Sep 2022

What is the effect of the Omicron variant on olfaction?

A new study discusses the effect of the Omicron variant of the virus on the olfactory system in humans.

15 Sep 2022

COVID-19's future is uncertain as infections increase and tracking decreases

Researchers review how the SARS-CoV-2 genome has changed throughout the COVID-19 pandemic.

14 Sep 2022

Mechanism of action of different COVID-19 vaccines

In a recent study posted to the bioRxiv* preprint server, researchers at the University of Tuebingen and Imperial College London assessed humoral and cellular immune responses elicited by the recombinant adenoviral vector (rAdVV)- and messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines.

14 Sep 2022

Research shows a complex relationship between vaping and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, researchers at the University of California, Riverside investigated the effects of electronic cigarette (EC) use as a risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

SARS-CoV-2 RNA and antibody detection in infected mothers’ breast milk

In a recent study published in the Journal of Medical Virology, Italian researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) and antibodies (Abs) in the milk of breastfeeding mothers with SARS-CoV-2 infections.

14 Sep 2022

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

In a recent study posted to the bioRxiv* pre-print server, researchers from Washington University School of Medicine, Moderna, Inc, and the U.S. National Institutes of Health tested two bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on the messenger ribonucleic acid (mRNA) platform.

14 Sep 2022

Interactions between SIRT5 and SARS-CoV-2 Nsp14 protein

In a new study, researchers investigated the interactions between sirtuin 5 (SIRT5) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein (Nsp14) protein.

14 Sep 2022

What is the impact of COVID-19 treatments targeting intracellular Neu1?

In a new study, researchers assessed the impact of targeting intracellular Neu1 on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

COVID-19 risk substantially reduced in seniors who receive 4th mRNA booster

In a recent study published in the Annals of Internal Medicine, researchers in Singapore estimated the effectiveness of the second booster (fourth dose) vaccination with messenger ribonucleic acid (mRNA) vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections with the SARS-CoV-2 Omicron variant and associated hospitalizations with among individuals aged ≥80 years.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022